Decoding Alzheimer’s at the crossroads of science and policy

This World Alzheimer’s Day, Anand Vairavan, Managing Director of Roche Diagnostics Australia, and Professor Matthew Kiernan, CEO of Neuroscience Research Australia (NeuRA) and a renowned expert in neurodegenerative diseases, speak candidly on the intersection of science, policy, and human experience.

The conversation moves from personal motivations to the collective, examining how clinicians, researchers, and industry came together during NeuRA’s first Industry Open Day to confront the pressing issues in Alzheimer’s care. There are revelations about gaps in the healthcare system, the readiness of clinicians to adopt new therapies, and the infrastructure required to truly make innovative health technologies accessible.

Roche Diagnostics’ two decades of research into Alzheimer’s provide another lens, as Vairavan reflects on findings that could shift how the disease is diagnosed and understood. Professor Kiernan delves into the impact of policy decisions, including the recent PBAC rejection of Lilly’s Alzheimer’s therapy, exploring the ripple effects.

At its heart, the conversation returns to the human side of Alzheimer’s. Patients, families, and carers navigate a labyrinth of uncertainty, confronting challenges that demand urgent answers. What can – and must – state governments and a re-elected Labor government deliver in partnership with key stakeholders to meet this pressing human need?

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.